P53allelic loss and outcome in patients with squamous cell carcinoma of the head and neck
✍ Scribed by J. P. Rodrigo; Eliecer Coto; María V. González; Miguel Maldonado; Carlos Suárez
- Publisher
- Springer-Verlag
- Year
- 2001
- Tongue
- English
- Weight
- 41 KB
- Volume
- 258
- Category
- Article
- ISSN
- 0302-9530
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Background. Treatment of head and neck squamous cell carcinoma (HNSCC) addresses the primary tumor and the lymphatic drainage. Modalities for the neck are neck dissection and/or radiation therapy. In most cases, the neck is treated by the modality that seems more appropriate for the
Background. Comorbid conditions have a significant impact on the actuarial survival of patients with head and neck cancer. However, no studies have evaluated the impact of comorbidity on tumor-and treatment-specific outcomes. This study was performed to evaluate the impact of comorbidity, graded by
## Background: A critical factor for successful organ preservation treatment in head and neck cancer may be selecting tumors that respond to chemotherapy and radiation. previous results in patients indicated that tumors that overexpressed p53 were more sensitive to chemotherapy than those that did
## Abstract ## Objectives This study aims at investigating the prognostic values of serum p53 protein and anti‐p53 antibody in patients undergoing surgical treatment for head and neck squamous cell carcinoma (HNSCC). ## Methods Serum p53 protein and anti‐p53 antibody concentrations were determin